Wonbiogen Co.,Ltd.

Wonbiogen Co.,Ltd.

KKRX:307280
5,590.00
KRW
+70.00
(+1.27%)
1,206.53EPS
4.57P/E
37.50BMarket Cap
Mar 24Next Earn
Wonbiogen Co.,Ltd.
KRX:307280
(Korea Stock Exchange)

Recent

price

5,590.00

P/E

ratio

4.57

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
- -
2,591.59
2,597.98
3,754.23
4,228.97
21,453.43
4,970.78
5,416.12
Revenue per Share
-124.2
50
-2,515
-105
450
785
4,010
933
1,206.75
Basic EPS, GAAP
-163.99
-62.64
22.9
-184.13
-110.34
442.77
5,768.59
911.36
-218.98
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
49.92
499.83
100.02
- -
Dividend per Share
9,105.36
9,155.37
-4,606.01
3,662.55
3,841.64
4,541.8
5,244.41
6,265.55
6,578.12
Book Value per Share
9,105.36
9,155.37
-5,203.67
3,535.18
3,707.93
4,407.23
5,142.88
6,185.28
6,499.48
Tangible Book Value per Share
- -
1
5
7
7
7
1
7
7
Basic Weighted Avg Shares
- -
- -
12,018
17,721
26,748
29,615
30,440
35,244
37,804
Sales/Revenue/Turnover
- -
- -
20.74
11.51
19.26
24.05
21.05
23.24
25.33
Operating Margin (%)
- -
- -
731
882
1,199
1,569
1,647
1,507
1,536
Depreciation Expense
-28
37
-11,662
-716
3,206
5,497
5,690
6,615
8,423
Net Income, GAAP
- -
22
- -
- -
10.75
16.71
16.87
16.99
16.38
Effective Tax Rate (%)
- -
- -
-97.04
-4.04
11.99
18.56
18.69
18.77
22.28
Profit Margin (%)
7,836
7,913
-12,703
11,990
6,621
11,790
18,350
22,560
16,187
Working Capital
1,036
1,065
73
326
254
690
479
314
1,829
LT Debt
6,774
6,812
-3,427
26,561
26,826
32,625
37,268
42,624
44,675
Total Equity
- -
-0.49
- -
- -
13.15
15.73
13.76
16.18
17.67
Return on Invested Capital (%)
- -
0.76
- -
- -
12.1
13.51
15.59
16.66
18.96
Return on Capital (%)
- -
0.55
- -
- -
11.97
18.61
16.39
16.55
20.03
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
617
682
2,716
LT Borrowings
- -
1,500
1,500
LT Finance Leases
314
258
329
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
45,552
48,348
37,501

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
27,071
24,850
23,387
Cash, Cash Equivalents & STI
15,360
13,390
11,151
Accounts Receivable, Net
5,347
5,179
5,541
Inventories
5,898
5,788
6,294
Total Current Liabilities
4,511
5,764
7,200
Payables & Accruals
- -
- -
- -
ST Debt
617
682
2,716
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-164.78%
14.37%
Free Cash Flow
- -
-334.29%
-21.05%
Net Income, GAAP
- -
-110.06%
16.27%
Sales/Revenue/Turnover
- -
25.54%
15.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,071
7,995
6,863
8,510
30,440
2025
8,255
8,397
9,219
9,374
35,244
2026
9,281
9,931
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
150
1,155
995
224.35
4,010
2025
875
226
307.05
224.08
933
2026
241.09
438.66
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
499.83
2025
- -
- -
- -
- -
100.02
2026
- -
- -
- -
- -
- -
Business
Wonbiogen Co.,Ltd. is a South Korea-based medical device and biotechnology company that specializes in the research, development, and manufacturing of advanced wound care dressings and medical-grade biomaterials. The company offers a diversified portfolio of polymer-based wound management and dermatological products, including hydrophilic polyurethane foam dressings for surgical wounds, burns, and chronic ulcers, marketed under the Therasorb and Medisorb brand lines; antibacterial silver-impregnated dressings such as Therasorb Silver Net and Medisorb AG+; hydrocolloid wound dressings and spot patches under the Renoderm and Medisorb H brands; silicone-based scar management gels and sheets under the Remscar brand; adhesive medical tapes and protective skin coverings under the Hiperskin line; and specialized cosmeceuticals and medical barrier creams, including the Kirier line and UV-protecting blemish patches. In addition to its proprietary branded offerings, the company provides original equipment manufacturing (OEM) and original design manufacturing (ODM) services for pharmaceutical and healthcare enterprises. Wonbiogen serves clinical, hospital, pharmacy, and consumer retail channels in South Korea and exports to international markets across Europe, North America, the Middle East, and Southeast Asia, including Germany, the United Kingdom, the United States, China, Indonesia, Turkey, and the United Arab Emirates. In recent developments, Wonbiogen has reinforced its commercial partnerships through an exclusive domestic distribution agreement with Humedix Co., Ltd., a subsidiary of Huons Group, for its Kirier wound barrier protection line; expanded its mass-production infrastructure for bio-friendly polyurethane wound dressings; diversified its research and development pipeline into surgical anti-adhesion barriers; and advanced its global regulatory footprint through ongoing compliance with international quality standards including ISO 13485, ISO 22716, CE marking, and U.S. FDA registrations. Wonbiogen Co.,Ltd. was founded in 2006 and is headquartered in Gumi, South Korea.